Close Menu

NEW YORK — VolitionRx said today that it has received  $1.4 million in non-dilutive funding through a grant from the Wallonia region of Belgium where the company is headquartered.

Unlike a recent $700,000 grant from Wallonia, this latest award is non-repayable, VolitionRx said. To date, the region has given the company about $6 million in non-dilutive funding.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.